

# Gerbode Ventricular Septal Defect –A Rare Cardiac Anomaly Associated with Genetic Variants in Indian Population- A Case Series

YASHVANTHI BORKAR<sup>1</sup>, KRISHNANANDA NAYAK<sup>2</sup>, RANJAN K. SHETTY<sup>3</sup>, GOPALAKRISHNA BHAT<sup>4</sup>, RAJASEKHAR MOKA<sup>5</sup>

## ABSTRACT

Gerbode defects are rare Ventricular Septal Defects (VSD) constituting approximately one percent cases of congenital heart diseases. The genetic predispositions towards the Gerbode Defect (GD) have remained an unexplored area of study till date. We investigated the genotype-phenotype correlation in patients with Gerbode VSD. Molecular genetic study on Sanger sequencing and subsequent data analysis showed that the contributing sequence variations in the *NKX2-5*, *GATA4* and *TBX5* gene lies in one of the highly conserved regions and this region is responsible for encoding a functional protein. The resulting genotype variation may be responsible for causing the diseased phenotype known as GD.

**Keywords:** Echocardiography, Single nucleotide polymorphism, Transcriptional gene(s).

VSD is the most common defect that occurs as a primary anomaly, with or without associated major cardiac defects [1]. Gerbode defect, a rare VSD “left ventricular-to-right atrial shunt” accounts for 1% in congenital heart diseases [2]. The diagnosis of an Left Ventricle-Right Atrial (LV-RA) shunt is always challenging due to the limited diagnostic accuracy of 2D Echocardiography [3]. GD results in either congenital or acquired defect where congenital GD result from an indirect shunt i.e., intravalvular via perimembranous ventricular septum and the acquired GD results from direct shunt i.e., supravulvular via membranous ventricular septum [4,5]. Acquired GD have been described as a complication related to bacterial endocarditis, chest injuries, and myocardial infarctions and Congenital GD (CGD) follows a complex developmental process and is caused by multiple factors [6]. In some individuals, smaller defects gradually close on their own by the process of an aneurysm occurring by means of hyperplasia of connective tissue covering the leaflets of tricuspid valve touching the margin of the defect [7]. In due course of time, failure in closing may lead to other complications. Despite major advancements in the field of genetic analysis, there is still a lack of consensus among investigators regarding the number of genes responsible for the rare phenotypes such as CGD.

The septum formation is an important milestone in the heart morphogenesis, which is highly orchestrated by transcriptional factor genes mainly *NKX2-5*, *GATA4*, and *TBX5* [8]. Several mutations in these transcription factor genes have been reported to lead to the cardiac septal defects [9]. The specific factors leading to complex VSDs remain unidentified till date. Understanding the aetiology and risk factors behind CGD, considering its multifactorial nature, becomes very important for assessing the implications of the defect [10,11]. Various studies have shown that the VSDs could be related to the sequence variations in patients and related families [12-14]. Through the present case series, we tried to find a correlation between the sequence variations in the *NKX2-5*, *GATA4* and *TBX5* genes and the role of these variations in causing GD. For this purpose, affected individuals with cardiac septal defects were assessed using two dimensional Transoesophageal Echocardiography (2DE-TEE) with colour flow Doppler and studied the three genes using automated DNA sequencing [15], so we sequenced the exon region along with the intron-exon boundaries of the subjected genes in three cases to explore the pathogenicity of the GD.

## CASE 1

A 31-year-old asymptomatic male with 7 mm moderate sized perimembranous VSD showing mild Tricuspid Regurgitation and moderate Pulmonary Arterial Hypertension. The echocardiography of the patient is represented in [Table/Fig-1]. The left to right shunt was found to be directed to Right Atrium (RA) through the tricuspid valve. Also, mildly dilated cardiac chambers with a forming aneurysm were observed to direct the VSD jet into RA and Right Ventricle (RV). On comprehensive mutation screening of all the coding exons and flanking introns of *NKX2-5*, *GATA4* and *TBX5*, we found the changes in *NKX2-5*, *GATA4* and *TBX5* genes to be as: 1) Two single nucleotide polymorphisms c.63A>G (exon 1) and c.543G>A (exon 2) of *NKX2-5* gene; 2) intronic SNP, g.79862C>T in the intron-exon boundaries of exon6 of *GATA4* gene; 3) c.215C>A (exon 3) of *TBX5* gene in this patient. Localization of sequence variants irrespective of conserved domains is represented in [Table/Fig-2a].

## CASE 2


A 27-year-old female having a complaint of murmur and 4 mm small perimembranous VSD associated right atrial dilation and mild to moderate Pulmonary Stenosis (PS). Further, it was observed that the colour flow jet was directed from RV into RA with 110 mmHg pressure gradients. Upon mutation analysis, we found the sequence variants of *NKX2-5*, *GATA4* and *TBX5* gene depicted in [Table/Fig-2b] are: 1) two synonymous SNPs in *NKX2-5* (c.63A>G; c.543G>A), non-synonymous variant (c.419C>T); 2) intronic variant (g.79862C>T) in the intron-exon boundaries of exon6 of *GATA4*; 3) mutation c.215C>A (exon 3) and a polymorphism; c.837A>G (exon 8) in *TBX5* gene, in this patient.

## CASE 3


A 55-year-old female having a fever with severe palpitations and with no cardiac complaints, diagnosed with 5 mm perimembranous Gerbode VSD along with moderate Pulmonary arterial hypertension. Transthoracic and Transoesophageal echocardiography further confirmed the presence of intracardiac shunt from Left Ventricle (LV) to RA. The Doppler gradient was 130 mmHg in right atrium with an aneurysmal formation which was confirmed by sonography. On mutation screening, we found the changes in *NKX2-5*, *GATA4* and *TBX5* genes to be: 1) two synonymous variants in *NKX2-5*

(c.63A>G; c.543G>A); 2) two non-synonymous variants (c.419C>T; c.1138G>A) and an intronic variant (g.79862C>T) in the intron-exon boundaries of exon6 of *GATA4*, and 3) polymorphism, c.837A>G (exon 8) in *TBX5* gene, in this patient.

The cross species alignment of *NKX2-5*, *GATA4* and *TBX5* protein [Table/Fig-2c] showed the amino acid changes belong to an evolutionarily conserved region which highlights the functional importance of the amino acid. However, the mutant residue was not observed in other homologous sequences suggesting the mutation to be potentially damaging to the protein function. The details of the exonic position, location of sequence variations in the secondary structure and prediction by in silico analysis are represented in



**[Table/Fig-1]:** Transthoracic echocardiography of the patient (Case 1) showing Indirect Gerbode VSD: a) Parasternal long axis view showing VSD with the aneurysmal formation. b) Apical four-chamber view with colour flow mapping showing VSD jet to RA and RV.




**[Table/Fig-2]:** A schematic representation of *NKX2-5* and *GATA4* sequence variants. A) Conserved domains of *NKX2-5*, *GATA4* and *TBX5* showing the location of sequence variants; a) *NKX2-5* protein indicates Tinman domain (TN), Homeobox Domain (HD) and NK domain; b) *GATA4* protein indicates Transactivation Domains (TAD), N-terminal zinc finger (NZf), C-terminal zinc finger (CZf), and nuclear localization signal (NLS); c) *TBX5* protein domains indicates DNA-binding domain (DNA-BD), transactivation domains (TAD and nuclear localization signal (NL) B) Sequence Chromatograms of *NKX2-5*, *GATA4*, and *TBX5*, arrows indicates the heterozygous nucleotides. a) c.63A>G, b) c.543G>A of *NKX2-5*; c) c.419C>T d) c.1138G>A e) g.79862C>T of *GATA4* and f) c.215C>A g) c.837A>G of *TBX5*. C) ConSurf analysis representing Multiple Sequence Alignment across different species showing the conserved and variable regions of the variants; a) *NKX2-5*; b) *GATA4* and c) *TBX5*.

[Table/Fig-3]. The structural analysis and protein modeling revealed that the wild type residue A346 to be located at Nuclear Localization Signal (NLS), and V380 at C-domain of *GATA4*. Upon mutation, both A346 and V380 are likely to make new hydrogen bond (H-bond) interaction i.e., A346 upon mutation converted to V346, makes 3 new H-bonds with Q316. This mutation has a peptide backbone with GLN316. Two H-bonds are formed between peptide backbone O of V346 with NE2 side chain and N of Q316 and third H-bond is between N of V346 and O of G316 [Table/Fig-4a]. In the proper conformation of V380, the bond is held with S379 and S381. However, upon mutation to M380, H-bond forms between N of M380 and O of S377 and between O of M380 and O side chain of S381 [Table/Fig-4b]. In the case of T72K, the wild type residue is located at T-box domain and consists of a DNA binding site. The interaction between T72 and I212 is relatively stronger than its interaction with P67 because of a H-bond. Mutation to K72 sterically hinders the K72 having a backbone of H68 and O backbone of W64, which results in structural and conformational changes in the protein [Table/Fig-4c].

**DISCUSSION**

We identified previously known genetic variants of isolated heart septal defects in *NKX2-5* (c.63A>G, c.543G>A); *GATA4* (c.419C>T, c.1138G>A and g.79862C>T) and *TBX5* (c.215C>A, c.837A>G) in CGD patients using Sanger sequencing utilizing genomic DNA of



**[Table/Fig-4]:** Detailed representation of *GATA4* and *TBX5* missense variants. Hydrogen bonds, weak hydrogen bonds, and steric clashes are shown in green dotted lines, gray dotted lines and pink dotted lines respectively. a) A346 mutation to V (A346V). b) V380 mutation to M (V380M). c) T72 mutation to K (T72K).

Gene Name	Chr. Loci	Exons	Genomic change	cDNA change	Allele change	Protein change	Amino acid change	RS/HGMD ID	Start	End	Helix	Strand	Coil	Case 1	Case 2	Case 3
NKX2-5	5	Exon1	g.337A>G	c.63A>G	GAA => GAG	p.E21E	E [Glu] => E [Glu]	rs2277923	172662023	172662025	+	-	-	+	+	+
		Exon 2	g.2357G>A	c.543G>A	CAG => CAA	p.Q181Q	Q[Gln] => Q[Gln]	rs72554028	172660003	172660005	-	-	+	+	+	+
GATA4	8	Exon 6	g.80016C>T	c.419C>T	GCT => GTT	p.A346V	A[Ala] => V[Val]	rs115372595/CM076205	11614482	11614484	-	-	+	-	+	+
		Exon 6	g.80117G>A	c.1138G>A	GTG => ATG	p.V380M	V[Val] => M[Met]	rs114868912	11614583	11614585	-	-	+	-	-	+
		Intron 5-6	g.79862C>T	-	-	-	-	-	rs3729854	11614328	11614330	-	-	-	+	+
TBX5	12	Exon3	g.6590C>A	c.215C>A	ACG => AAG	p.T72K	T [Thr] => K [Lys]	rs863223779	114839657	114839659	+	-	-	+	+	-
		Exon 8	g.42133A>G	c.837A>G	CGA => CGG	p.R279R	R [Arg] => R[Arg]	rs564499369	11436639	114366311	-	-	+	-	+	+

**[Table/Fig-3]:** Genetic variants and their location in the secondary structure of protein associated with Gerbode defect patients. Footnotes: '+' indicates presence; '-' indicates absence.

Genes	Exons	Forward	Reverse	PCR product (bp)
NKX2-5	Exon1 <sup>a</sup>	5'GCCTCTCCTGCCCTTGCTGCT3'	5'GGACGAAAGCGACCCAGGAG3'	550 <sup>a</sup>
	Exon2 <sup>a</sup>	5'CCCTTACCATTACTGTGCGG3'	5'AGTCAGGGAGCTGTTGAGGTG3'	779 <sup>a</sup>
	Exon1 <sup>b</sup>	5'CCTTGTGCTCAGCGCTACCTG3'	5'CGACAACACCAGGCATCTTACATT3'	635
	Exon2 <sup>b</sup>	5'CTCCACGAGGATCCCTTACCATTA3'	5'GAGAGTCAGGGAGCTGTTGAGGTG3'	794
GATA4	Exon2 <sup>a</sup>	5'GATCTTCGCGACAGTTCTCTC3'	5'GTCCCCGGGAAGGAGAAG3'	458 <sup>b</sup>
	Exon2 <sup>b</sup>	5'GCTGGGCCTGTCTCTACCT3'	5'AAAAACAAGAGGCCCTCGAC3'	554 <sup>b</sup>
	Exon3	5'GGGCTGAAGTCAGAGTGAGG3'	5'GATGCACACCCTCAAGTTCC3'	437 <sup>b</sup>
	Exon4	5'GAGATCTCATGCAGGGTCGT3'	5'GCCCTTCCAAATCTAAGTC3'	390 <sup>b</sup>
	Exon5	5'TCTTTCTCGCTGAGTCCAG3'	5'GGATGTCCGATGCTGTC3'	379 <sup>b</sup>
	Exon6	5'GCCATCCCTGTGAGAACTGT3'	5'GAGGGTAGCTCACTGCTTGC3'	444 <sup>b</sup>
	Exon7	5'AAGTGCTCCTTGGTCCCTTC3'	5'TTCCCTAACCAGATTGTCG3'	479 <sup>b</sup>
TBX5	Exon1 <sup>a</sup>	5'GGTATTCATTTGCCAGAGC3'	5'CCCAGTAAAATAAAGAGGCAACC3'	478 <sup>c</sup>
	Exon1 <sup>b</sup>	5'CCAGCCAAACGTGACAGC3'	5'GCCAAGTGCAAAGAGAAACC3'	390 <sup>c</sup>
	Exon2	5'TTTCTCTCGTCTCTCTCTGTC3'	5'CAGACTCTGACTTTGATCTCTGC3'	297 <sup>c</sup>
	Exon3	5'GTGTTTTGGGGGAGTTGG3'	5'GCCACCTTTTCTTCTTACC3'	243 <sup>c</sup>
	Exon4	5'GAGGCTGCCTAAAATACTGG3'	5'AACTTTTTGGGAGAAGTTCC3'	248 <sup>c</sup>
	Exon5	5'CTGGTGCCTGAAGTGAAGC3'	5'GAGGACAAGAGGGAGACAAGG3'	282 <sup>c</sup>
	Exon6	5'GGGAGCAGGGTTTATCTGG3'	5'TGCAAAAGAAAGAGCAGACG3'	280 <sup>c</sup>
	Exon7	5'TGGCTTAATTTGCTCTTTGG3'	5'GGTTGCTGCTGGCTTACC3'	294 <sup>c</sup>
	Exon8	5'TCTCTCACACCTGGTTCAGC3'	5'ATACTCTCACCCCTCACC3'	390 <sup>c</sup>
	Exon9 <sup>a</sup>	5'TTGCCAAATAACTGTCTCC3'	5'GCTGGAACATTCCCTCTCC3'	465 <sup>c</sup>
	Exon9 <sup>b</sup>	5'ACTTCTCCGCTCACTTACC3'	5'TTTTTAAAATTGGTTTCAAGC3'	474 <sup>c</sup>

**[Table/Fig-5]:** PCR targeted primer sequences with product size for NKX2-5, GATA4 and TBX5.

<sup>a</sup> Pang et al., 2012; <sup>b</sup> Yang et al., 2012; <sup>c</sup> Granados-Riveron et al., 2012.

CGD patients isolated via the standard phenol chloroform method. Period in between PCR targeted primers were designed for whole exons and partial flanking introns of *GATA4*, *NKX2-5* and *TBX5* using Primer 3 software and amplified [Table/Fig-5]. The PCR amplicons were then sequenced by the Big Dye Terminator ABI Prism sequencing kit (Applied Biosystems, Foster City, CA, USA), and run on ABI 3130 XL sequencer. DNA Sequencing was performed twice to confirm the variants using both forward and reverse primers. The acquired raw sequences were compared using NCBI BLAST and CLUSTAL W. The variations were then characterized for functional analysis using insilico tools such as SIFT, PANTHER, PolyPhen-2, Provean, I-Mutant to identify the sequence variation and its impact on the protein structure and function. Structural analysis and protein visualization for the missense variants was performed using Swiss-PDB viewer [16]. Cross species alignment of *NKX2-5*, *GATA4*, and *TBX5* protein sequences showed that the affected amino acids lying in the conserved regions, suggesting that the amino acid is functionally important [11]. However, the mutated amino acid was not among the most commonly found residue types, indicating the mutation to be potentially affecting the protein conformation which may lead to the pathogenesis of Gerbode VSD in these patients. Functional characteristics of these variants through in silico analysis suggested that c.419C>T (p. A346V) and c.1138G>A (p. V380M) are benign (PolyPhen-2) and tolerated (SIFT). However, c.215C>A (p. T72K) is found to be deleterious (SIFT) and damaging (PolyPhen-2) [17,18].

The missense mutation p.T72K has been previously reported in Saudi infant with Holt-Oram syndrome associated with congenital heart disease and found to be damaging to the *TBX5* protein [19]. I-mutant analysis of these non synonymous variants showed protein destabilization. However, the reported synonymous variant c.63A>G of *NKX2-5* in the present study alters the functional and conformational characteristics of the encoded protein [20]. Sequence variations in the *NKX2-5* (c.63A>G, c.543G>A) and *GATA4* (c.419C>T) genes have been reported to be associated with heart septal defects such as VSD and having similar implications

has been observed in CGD patients in the present study [21,22]. However, the implications of missense variant c.1138G>A and the synonymous variant of *TBX5*, c.837A>G have been reported earlier in sporadic septal defects and non syndromic atrioventricular septal defect, respectively [23,24].

C-domain of *GATA4* protein plays a major role in regulating the transcriptional activity. However, two non-synonymous variants (c.419C>T and c.1138G>A) in our case series are in the NLS and C-domain of *GATA4* which may influence the transcriptional activity by altering the molecular mechanism of *GATA4* [1,24]. The non-synonymous SNPs are documented to cause amino acid alterations resulting into the loss of protein structure and functions, causing altered phenotype [25]. But, in our study, the tertiary structure of the protein changes due to the alteration in the side chains of A346 and V380 of *GATA4* and T72 of *TBX5*. The distribution of the polar and nonpolar amino acids directs the protein tertiary structure. These changes may not directly inactivate the protein rather bringing subtle changes in the protein activity due to their interaction with the neighbouring proteins. In this study, the side chains variation and change in the 3D structure of amino acids [Table/Fig-4] suggests their potential role in non functionality of *GATA4* and *TBX5* proteins [25]. Our analysis suggests that the genetic variants identified in these cardiac genes may contribute to the pathogenesis of CGD by altering the gene and the protein expression.

## CONCLUSION

We hereby report three cases with rare congenital GD with abnormalities such as tricuspid regurgitation, intracardiac shunt, and pulmonary artery hypertension. Molecular analysis may help to enrich the understanding of pathogenesis involved in the GD. To the best of our knowledge, this study is the first to investigate and detect gene sequence variants in CGD cases. Further investigations of genetic variations in confirmed CGD will strengthen these findings and enrich our understanding of cardiac specific transcription factors and their role in organogenesis.

## ACKNOWLEDGEMENTS

We thank our patients and their family for their cooperation. We are grateful to Director, School of Life Sciences for his support and encouragement to complete this study. We appreciate our colleagues' cooperation and finally we acknowledge Manipal University (Structured Ph.D.) for infrastructure and ICMR, New Delhi (54/23/2012-HUM/BMS) for financial support.

## REFERENCES

- [1] Wang J, Fang M, Liu XY, Xin YF, Liu ZM, Chen XZ, et al. A novel GATA4 mutation responsible for congenital ventricular septal defects. *Int J Mol Med*. 2011;28(4):557-64.
- [2] Yuan SM. Acquired left ventricle-to-right atrium shunt: Clinical implications and diagnostic dilemmas. *Wien Klin Wochenschr*. 2015;127(21-22):884-92.
- [3] Yuan SM. Left ventricular to right atrial shunt (Gerbode defect): Congenital versus acquired. *Postepy Kardiologii Interwencyjnej*. 2014;10(3):185-94.
- [4] Demirkol S, GurkanYesil F, Bozlar U, Balta S, Sahin MA, Guler A. Multimodality imaging of a congenital Gerbode defect. *Kardiologia Pol*. 2013;71(1):104.
- [5] Panduranga P, Mukhaini M. A rare type of Gerbode defect. *Echocardiography*. 2011;28(6):E118-120.
- [6] Prifti E, Ademaj F, Baboci A, Demiraj A. Acquired Gerbode defect following endocarditis of the tricuspid valve: A case report and literature review. *J Cardiothorac Surg*. 2015;10:115.
- [7] Gosciniak P, Larysz B, Baraniak J, Jozwa R, Zych A, Mokrzycki K, et al. The Gerbode defect- A frequent echocardiographic pitfall. *Kardiologia Polska*. 2012;70(11):1191-93.
- [8] McCulley DJ, Black BL. Transcription factor pathway and congenital heart disease. *Curr Top Dev Biol*. 2012;100:253-77.
- [9] Granados-Riveron JT, Pope M, Bu'Lock FA, Thornborough C, Eason J, Setchfield K, et al. Combined mutation screening of *NKX2-5*, *GATA4*, and *TBX5* in congenital heart disease: Multiple heterozygosity and novel mutations. *Congenit Heart Dis*. 2012;7(2):151-59.
- [10] Blue GM, Kirk EP, Sholler GF, Harvey RP, Sinlaw DS. Congenital heart disease: Current knowledge about causes and inheritance. *Med J Aust*. 2012;197(3):155-59.
- [11] Winston JB, Schulkey CE, Chen IBD, Regmi SD, Efimova M, Erlich JM, et al. Complex Trait Analysis of Ventricular Septal Defects Caused by *Nkx2-5* Mutation. *Circ Cardiovasc Genet*. 2012; 5(3): 293-300.
- [12] An Y, Duan W, Huang G, Chen X, Li L, Nie C, et al. Genome-Wide copy number variant analysis for congenital ventricular septal defects in Chinese Han population. *BMC Med Genomics*. 2016;9:2.
- [13] Pang S, Shan J, Qiao Y, Ma L, Qin X, Wanyan H, et al. Genetic and functional analysis of the *nkx2-5* gene promoter in patients with ventricular septal defects. *Pediatr Cardiol*. 2012;33(8):1355-61.
- [14] Yang YQ, Wang J, Liu XY, Chen XZ, Zhang W, Wang XZ, et al. Novel GATA4 mutations in patients with congenital ventricular septal defects. *Med Sci Monit*. 2012;18:CR344-50.
- [15] Sanger F, Coulson AR. A rapid method for determining sequences in DNA by primed synthesis with DNA polymerase. *J Mol Biol*. 1975;94(3):441-48.
- [16] Guex N, Peitsch MC. SWISS-MODEL and the Swiss-Pdb Viewer: An environment for comparative protein modelling. *Electrophoresis*. 1997;18(15):2714-23.
- [17] Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, et al. A method and server for predicting damaging missense mutations. *Nat Methods*. 2010;7(4):248-49.
- [18] Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. *Nat Protoc*. 2009;4(7):1073-81.
- [19] Al-Qattan MM, Abou Al-Shaar H. A novel missense mutation in the *TBX5* gene in a Saudi infant with Holt-Oram syndrome. *Saudi Med J*. 2015;36(8):980-82.
- [20] Sauna ZE, Kimchi-Sarfaty C. Understanding the contribution of synonymous mutations to human disease. *Nat Rev Genet*. 2011;12(10):683-91.
- [21] Yashvanthi B, Ranjan KS, Krishnananda K, Rajasekhar M. Molecular genetic study on heart septal defects. *Journal of Global Biosciences*. 2016;5(1):3475-82.
- [22] Wang Z, Zou L, Zhong R, Zhu B, Chen W, Shen N, et al. Associations between two genetic variants in *NKX2-5* and risk of congenital heart disease in Chinese population: A meta-analysis. *PLoS One*. 2013;8(8):e70979.
- [23] Schluterman MK, Krysiak AE, Kathirya IS, Abate N, Chandalia M, Srivastava D et al. Screening and biochemical analysis of GATA4 sequence variations identified in patients with congenital heart disease. *Am J Med Genet A*. 2007;143A(8):817-23.
- [24] Reamon-Buettner SM, Borlak J. *TBX5* mutations in non-Holt-Oram syndrome (HOS) malformed hearts. *Hum Mutat*. 2004;24(1):104.
- [25] Manjegowda DS, Karunakar P, Ramachandra NB. Effect of structural changes in proteins derived from GATA4 nonsynonymous single nucleotide polymorphisms in congenital heart diseases. *Indian J Pharm Sci*. 2015;77(6):735-41.

### PARTICULARS OF CONTRIBUTORS:

1. PhD Scholar, Department of Cellular and Molecular Biology, School of Life Sciences, Manipal University, Manipal, Karnataka, India.
2. Assistant Professor and Head, Department of Cardiovascular Therapy, School of Allied Health Sciences, Manipal University, Manipal, Karnataka, India.
3. Professor and Head, Department of Cardiology, Kasturba Medical College, Manipal, Karnataka, India.
4. Professor, Department of Biotechnology, School of Life Sciences, Manipal University, Manipal, Karnataka, India.
5. Associate Professor, Department of Cellular and Molecular Biology, School of Life Sciences, Manipal University, Manipal, Karnataka, India.

### NAME, ADDRESS, E-MAIL ID OF THE CORRESPONDING AUTHOR:

Dr. Rajasekhar Moka,  
Associate Professor, Department of Cellular and Molecular Biology, School of Life Sciences, Manipal University,  
Manipal-576104, Karnataka, India.  
E-mail: rsmoka@gmail.com

Date of Submission: **Aug 30, 2016**

Date of Peer Review: **Oct 17, 2016**

Date of Acceptance: **Nov 17, 2016**

Date of Publishing: **Mar 01, 2017**

FINANCIAL OR OTHER COMPETING INTERESTS: None.